Approved Formulary
Add Formweb to your mobile device
Approved Formulary
Do Not Crush Do not crush extended release tablets or capsules. Capsules may be opened and contents taken without crushing or chewing in soft food. Capsule contents may be administered via NG using appropriate fluid.
Search results for:
METHYLPHENIDATE
METHYLPHENIDATE
| Drug Name | Form | Strength | Non-Formulary | Notes |
|---|---|---|---|---|
| METADATE CD | CAPSULE, EXTENDED RELEASE | 10 MG | ||
| RITALIN LA | CAPSULE, EXTENDED RELEASE | 10 MG | ||
| METADATE CD | CAPSULE, EXTENDED RELEASE | 20 MG | ||
| RITALIN LA | CAPSULE, EXTENDED RELEASE | 20 mg | ||
| METADATE CD | CAPSULE, EXTENDED RELEASE | 30 MG | ||
| RITALIN LA | CAPSULE, EXTENDED RELEASE | 30 mg | ||
| RITALIN LA | CAPSULE, EXTENDED RELEASE | 40 MG | ||
| METHYLPHENIDATE HYDROCHLORIDE | TABLET | 10 mg | ||
| RITALIN | TABLET | 20 mg | ||
| METADATE ER | TABLET, EXTENDED RELEASE | 10 MG | ||
| CONCERTA | TABLET, EXTENDED RELEASE | 18 mg/24 hr | ||
| METADATE ER | TABLET, EXTENDED RELEASE | 20 MG | ||
| RITALIN-SR | TABLET, EXTENDED RELEASE | 20 mg | ||
| CONCERTA | TABLET, EXTENDED RELEASE | 27 mg/24 hr | ||
| CONCERTA | TABLET, EXTENDED RELEASE | 36 mg/24 hr | ||
| CONCERTA | TABLET, EXTENDED RELEASE | 54 MG/24 hr | ||
| DAYTRANA | TRANSDERMAL PATCH | 30 mg/9 hour |
View Other Therapeutic Options: Respiratory and CNS Stimulants:
282032
Last updated: Aug. 5, 2015
- Do Not Crush Do not crush extended release tablets or capsules. Capsules may be opened and contents taken without crushing or chewing in soft food. Capsule contents may be administered via NG using appropriate fluid.
- Black Box Warning: Psychiatric effects
Class II
The topical patch (Daytrana) may cause permanent loss of skin color, ranging up to 8 inches in diameter. This is not thought to be reversible, and not physically harmful, but may cause emotional distress. If changes in skin color are noted, this should be reported to the health care provider.